Protein kinase a activation enhances β-catenin transcriptional activity through nuclear localization to PML bodies

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Zhang, Mei ^a   Mahoney, Emilia ^a   Zuo, Tao ^a   Manchanda, Parmeet K ^a   Davuluri, Ramana V ^b   Kirschner, Lawrence S ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT IALPHA; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; WNT PROTEIN; WNT5A PROTEIN; CREB1 PROTEIN, MOUSE; CTNNB1 PROTEIN, HUMAN; PRKAR1A PROTEIN, MOUSE; PROTEIN BINDING; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; ROR2 PROTEIN, MOUSE; WNT3A PROTEIN; WNT3A PROTEIN, MOUSE;

3T3 CELL LINE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE TUMOR; CELL NUCLEUS; CELL NUCLEUS INCLUSION BODY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GENE MUTATION; MOUSE; NONHUMAN; PML BODY; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; BONE; CYTOSOL; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; OSTEOBLAST; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; BETA CATENIN; BONE AND BONES; BONE NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASE RIALPHA SUBUNIT; CYTOSOL; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; OSTEOBLASTS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; WNT3A PROTEIN;

EID: 84907856880     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109523     Document Type: Article

References (44)

1. Siddappa R, Mulder W, Steeghs I, van de Klundert C, Fernandes H, et al. (2009) cAMP/PKA signaling inhibits osteogenic differentiation and bone formation in rodent models. Tissue Eng Part A 15: 2135-2143.
2. Westendorf JJ, Kahler RA, Schroeder TM (2004) Wnt signaling in osteoblasts and bone diseases. Gene 341: 19-39.
3. Rudolf R, Khan MM, Lustrino D, Labeit S, Kettelhut IC, et al. (2013) Alterations of cAMP-dependent signaling in dystrophic skeletal muscle. Front Physiol 4: 290.
4. von Maltzahn J, Chang NC, Bentzinger CF, Rudnicki MA (2012) Wnt signaling in myogenesis. Trends Cell Biol 22: 602-609.
5. Spiegel AM (1997) The molecular basis of disorders caused by defects in G proteins. Horm Res 47: 89-96.
6. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, et al. (1991) Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325: 1688-1695.
7. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, et al. (2000) Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 26: 89-92.
8. Salpea P, Stratakis CA (2014) Carney complex and McCune Albright syndrome: An overview of clinical manifestations and human molecular genetics. Mol Cell Endocrinol 386: 85-91.
9. Zhang S, Kaplan FS, Shore EM (2012) Different roles of GNAS and cAMP signaling during early and late stages of osteogenic differentiation. Horm Metab Res 44: 724-731.
10. Zhang M, Manchanda PK, Wu D, Wang Q, Kirschner LS (2014) Knockdown of PRKAR1A, the Gene Responsible for Carney Complex, Interferes With Differentiation in Osteoblastic Cells. Mol Endocrinol 28: 295-307.
11. Niehrs C The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol 13: 767-779.
12. Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426.
13. Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, et al. (2002) Axinmediated CKI phosphorylation of beta-catenin at Ser 45: A molecular switch for the Wnt pathway. Genes Dev 16: 1066-1076.
14. Yost C, Torres M, Miller JR, Huang E, Kimelman D, et al. (1996) The axisinducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 10: 1443-1454.
15. de Boer J, Siddappa R, Gaspar C, van Apeldoorn A, Fodde R, et al. (2004) Wnt signaling inhibits osteogenic differentiation of human mesenchymal stem cells. Bone 34: 818-826.
16. Cho HH, Kim YJ, Kim SJ, Kim JH, Bae YC, et al. (2006) Endogenous Wnt signaling promotes proliferation and suppresses osteogenic differentiation in human adipose derived stromal cells. Tissue Eng 12: 111-121.
17. Regard JB, Zhong Z, Williams BO, Yang Y (2012) Wnt signaling in bone development and disease: making stronger bone with Wnts. Cold Spring Harb Perspect Biol 4.
18. Wang Y, Li YP, Paulson C, Shao JZ, Zhang X, et al. (2014) Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci (Landmark Ed) 19: 379-407.
19. Hino S, Tanji C, Nakayama KI, Kikuchi A (2005) Phosphorylation of betacatenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol Cell Biol 25: 9063-9072.
20. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO (2006) Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 281: 9971- 9976.
21. Almeida MQ, Stratakis CA (2010) How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues? Mol Cell Endocrinol.
22. Chen AE, Ginty DD, Fan CM (2005) Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. Nature 433: 317-322.
23. Pavel E, Nadella K, Towns WH 2nd, Kirschner LS (2008) Mutation of Prkar1a causes osteoblast neoplasia driven by dysregulation of protein kinase A. Mol Endocrinol 22: 430-440.
24. Zhang M, Manchanda PK, Wu D, Wang Q, Kirschner LS (2014) Knockdown of PRKAR1A, the Gene Responsible for Carney Complex, Interferes With Differentiation in Osteoblastic Cells. Mol Endocrinol 28: 295-307.
25. Mohan RD, Rao A, Gagliardi J, Tini M (2007) SUMO-1-dependent allosteric regulation of thymine DNA glycosylase alters subnuclear localization and CBP/p300 recruitment. Mol Cell Biol 27: 229-243.
26. Bernardi R, Pandolfi PP (2007) Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 8: 1006-1016.
27. Satow R, Shitashige M, Jigami T, Fukami K, Honda K, et al. (2012) betacatenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells. Gastroenterology 142: 572-581.
28. Sun J, Fu S, Zhong W, Huang H (2013) PML overexpression inhibits proliferation and promotes the osteogenic differentiation of human mesenchymal stem cells. Oncol Rep 30: 2785-2794.
29. Kang MA, So EY, Ouchi T (2012) Deregulation of DNA damage response pathway by intercellular contact. J Biol Chem 287: 16246-16255.
30. Schiller PC, D'Ippolito G, Roos BA, Howard GA (1999) Anabolic or catabolic responses of MC3T3-E1 osteoblastic cells to parathyroid hormone depend on time and duration of treatment. J Bone Miner Res 14: 1504-1512.
31. Montminy M (1997) Transcriptional regulation by cyclic AMP. Annu Rev Biochem 66: 807-822.
32. Walkinshaw DR, Weist R, Xiao L, Yan K, Kim GW, et al. (2013) Dephosphorylation at a conserved SP motif governs cAMP sensitivity and nuclear localization of class IIa histone deacetylases. J Biol Chem 288: 5591- 5605.
33. Niida A, Hiroko T, Kasai M, Furukawa Y, Nakamura Y, et al. (2004) DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene 23: 8520-8526.
34. Kahler RA, Westendorf JJ (2003) Lymphoid enhancer factor-1 and beta-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter. J Biol Chem 278: 11937-11944.
35. Torii K, Nishizawa K, Kawasaki A, Yamashita Y, Katada M, et al. (2008) Antiapoptotic action of Wnt5a in dermal fibroblasts is mediated by the PKA signaling pathways. Cell Signal 20: 1256-1266.
36. Gupta R, Bhattacharyya A, Agosto-Perez FJ, Wickramasinghe P, Davuluri RV (2011) MPromDb update 2010: An integrated resource for annotation and visualization of mammalian gene promoters and ChIP-seq experimental data. Nucleic Acids Res 39: D92-97.
37. Kel AE, Gossling E, Reuter I, Cheremushkin E, Kel-Margoulis OV, et al. (2003) MATCH: A tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res 31: 3576-3579.
38. Mikels AJ, Nusse R (2006) Purified Wnt5a protein activates or inhibits betacatenin- TCF signaling depending on receptor context. PLoS Biol 4: e115.
39. Regard JB, Cherman N, Palmer D, Kuznetsov SA, Celi FS, et al. (2011) Wnt/beta-catenin signaling is differentially regulated by Galpha proteins and contributes to fibrous dysplasia. Proc Natl Acad Sci U S A 108: 20101-20106.
40. Brudvik KW, Paulsen JE, Aandahl EM, Roald B, Tasken K (2011) Protein kinase A antagonist inhibits beta-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in Apc(Min/+) mice. Mol Cancer 10: 149.
41. Satow R, Shitashige M, Jigami T, Fukami K, Honda K, et al. (2012) betacatenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells. Gastroenterology 142: 572-581.
42. Hildesheim J, Salvador JM, Hollander MC, Fornace AJ Jr. (2005) Casein kinase 2- And protein kinase A-regulated adenomatous polyposis coli and beta-catenin cellular localization is dependent on p38 MAPK. J Biol Chem 280: 17221- 17226.
43. Bordonaro M, Tewari S, Cicco CE, Atamna W, Lazarova DL (2011) A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells. PLoS One 6: e27308.
44. Ewan KB, Dale TC (2008) The potential for targeting oncogenic WNT/betacatenin signaling in therapy. Curr Drug Targets 9: 532-547.